Ascendis Pharma A (ASND) Gross Profit (2021 - 2026)

Over the twelve months ended Jun 30, 2026, Ascendis Pharma A's Gross Profit came in at $1.11 billion, up 146.0% year-over-year; for the year ended Dec 31, 2025, it was $706.38 million, up 81.3% from the prior year.

• Gross Profit has increased for four consecutive years, with a five-year compound annual growth rate of 143.3% (years ended Dec 2020 to Dec 2025).
• By year, Gross Profit came in at $389.65 million in the year ended Dec 31, 2024 (+62.0%), $240.49 million in the year ended Dec 31, 2023 (+484.5%), $41.14 million in the year ended Dec 31, 2022 (+745.2%) and $4.87 million in the year ended Dec 31, 2021 (-41.3%).
• The figure for the quarter ended Jun 30, 2026 ranks as the highest quarterly Gross Profit in data going back to the quarter ended Mar 31, 2021.
• Year over year, Gross Profit has now increased in each of the last five quarters, with growth averaging 153.9% over the last eight quarters.
• The high point for year-over-year Gross Profit in five years was the quarter ended Mar 31, 2023 (growth of 972.9%); the low point was the quarter ended Jun 30, 2024 (a decline of 29.6%).
• Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at $268.2 million (quarter ended Mar 31, 2026), $260.63 million (quarter ended Dec 31, 2025) and $223.62 million (quarter ended Sep 30, 2025).